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Abstract  
Background: To inform the development of the European Academy of Allergy and Clinical 
,PPXQRQRORJ\·V($$&,Guidelines on Allergen Immunotherapy (AIT) for allergic asthma, we assessed 
the evidence on the effectiveness, cost-effectiveness and safety of AIT.   
Methods: We performed a systematic review, which  involved searching nine databases.  Studies were 
screened against pre-defined eligibility criteria and critically appraised using established instruments.  Data 
were synthesized using random-effects meta-analyses. 
Results: 98 studies satisfied the inclusion criteria. Short-term symptom scores were reduced with a 
standardized mean difference (SMD) of -1.11 (95%CI -1.66, -0.56).  This was robust to a pre-specified 
sensitivity analyses, but there was evidence suggestive of publication bias. Short-term medication scores 
were reduced SMD -1.21 (95%CI -1.87, -0.54), again with evidence of potential publication bias.  There 
was no reduction in short-term combined medication and symptom scores SMD 0.17 (95%CI -0.23, 
0.58), but one study showed a beneficial long-term effect.  
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For secondary outcomes subcutaneous immunotherapy (SCIT) improved quality of life and decreased 
allergen specific airways hyperreactivity (AHR) but this was not the case for sub-lingual immunotherapy 
(SLIT). There were no consistent effects on asthma control, exacerbations, lung function, and non-
specific AHR.  
AIT resulted in a modest increased risk of adverse events (AEs). Although relatively uncommon, systemic 
AEs were more frequent with SCIT; however no fatalities were reported.  
The limited evidence on cost-effectiveness was mainly available for sublingual immunotherapy (SLIT) and 
this suggested that SLIT is likely to be cost-effective. 
Conclusions: AIT can achieve substantial reductions in short-term symptom and medication scores in 
allergic asthma.  It was however associated with a modest increased risk of systemic and local AEs.  More 
data are needed in relation to secondary outcomes, longer-term effectiveness and cost-effectiveness.  
 
Keywords: allergy, allergen immunotherapy, asthma, cost-effectiveness, desensitization, effectiveness, 
exacerbations, lung function, quality of life, safety. 
 
BACKGROUND  
Asthma is a major public health problem affecting over 300 million people worldwide.(1) Its prevalence 
and impact are particularly on the rise and it is estimated that by 2025 an additional 100 million people 
may develop asthma.(2) Asthma  LVWKHUHIRUHVHWWREHFRPHRQHRIWKHZRUOG·V most prevalent chronic 
diseases. 
Based on the clinical history, examination and investigative procedures, different asthma phenotypes have 
been described.(3)  The pathogenesis of asthma is extremely complex and several disease endotypes have 
been suggested.(3,4) Allergic asthma is one of best described asthma phenotypesof primary studies. 
Allergic sensitization is a strong risk factor for asthma inception and severity in children and in adults.(5) 
Current asthma therapies can effectively control symptoms and the ongoing inflammatory process but do 
not affect the underlying, dysregulated immune response. Thus, they are very limited in controlling the 
progression of the disease. Allergen immunotherapy (AIT) is the only etiology-based treatment for 
allergic diseases capable of disease modification, as demonstrated by prevention of both the onset of new 
allergic sensitizations and disease progression.  
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The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
Guidelines on Allergen Immunotherapy (AIT) for Allergic Asthma.  We undertook a systematic review of primary 
studies on the effectiveness, cost-effectiveness and safety of AIT for allergic asthma in order to inform 
the formulation of key clinical recommendations.    
METHODS  
A detailed outline of the methods have previously been published in the protocol of this review.(6) We 
therefore confine ourseleves to a synopsis of the methods employed.   
A highly sensitive search strategy was developed, and validated study design filters were applied to retrieve 
articles pertaining to the use of AIT for  allergic asthma from electronic bibliographic databases.  The 
search strategy was developed on OVID MEDLINE and then adapted for the other databases (see 
Appendix 1, Supplementary file). In all cases, the databases were searched from inception to October 31, 
2015.  Additional papers were located through searching the references cited by the identified studies, and 
unpublished work and research in progress was identified through discussion with experts in the field.   
There were no language restrictions employed.  
Inclusion  and exclusion criteria are detailed in Box 1 
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Patient 
characteristics 
 
Studies conducted on patients of any age with a physician confirmed diagnosis of asthma, 
plus evidence of clinically relevant allergic sensitization as assessed by an objective 
biomarker (e.g., skin prick test or specific-IgE), in combination with a history of asthma 
symptoms due to allergen exposure 
Interventions 
of interest  
 
AIT for different allergens (e.g. pollens, house dust mites (HDM), animal dander, 
cockroach and molds), administered through either subcutaneous (SCIT) or sublingual 
(SLIT) routes. 
Comparator Placebo or any active comparator. 
Study designs  
 
Effectiveness: Double-blind randomized controlled trials (RCTs). Originally, we planned to 
include data from any RCT, irrespective of whether there was blinding.  This was changed 
due to the large volume of RCT studies. This decision was made prior to any analyses being 
undertaken.  
Cost-effectiveness: Health economic analysis.  
Safety: Double-EOLQG5&7VDQGODUJHFDVHVHULHVSDWLHQWV. 
Outcomes 
 
Primary outcomes: Effectiveness, both short-term (i.e. during treatment) and long-term (i.e. at 
least a year after discontinuation of AIT)  as assessed by symptom and/or medication 
scores.   
Secondary outcomes: Asthma control; asthma specific quality of life (QoL); exacerbations; lung 
function; response to environmental exposure chamber or bronchial allergen challenge; 
health economic analysis from the perspective of the health system/payer; and safety as 
assessed by local and systemic reactions.(7,8) 
Exclusion 
criteria 
Reviews, discussion papers, non-research letters and editorials, animal studies and studies 
not employing double-blind RCT designs. 
 
Box 1. Inclusion and exclusion criteria 
 
Study selection 
All references were uploaded into the systematic review software DistillerSR and underwent de-
duplication.  Studies were independently checked by two reviewers (SD, FA or AK) against the above 
inclusion criteria. Any discrepancies were resolved through discussion and, when necessary, a third 
reviewer was consulted (AS).   
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Quality assessment 
Quality assessments were independently carried out on each study by two reviewers (FA, AK, DD, SD or 
MK).  We used the Cochrane Risk of Bias (ROB) tool to assess RCTs,(9) the Critical Appraisal Skills 
Programme (CASP) Economic Evaluation Checklist for health economic studies ,(10) and the National 
Institute for Health and Clinical Excellence (NICE) quality assessment tool to critically appraise case 
series.(11) Any discrepancies were resolved by discussion or arbitration by a third reviewer (AS). 
 
Data extraction, analysis and synthesis 
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers (FA, AK, HZ, DD or SD) and any discrepancies were resolved by discussion or arbitration by a 
third reviewer (AS).  A descriptive report with summary data tables was produced to summarize the 
literature.  Where clinically and statistically appropriate, meta-analyses were undertaken using random-
effects modeling.(12) Where standardized mean difference (SMD)has been used the scale used is 0.2 
represents a small effect size, 0.5 a medium effect size and 0.8 a large effect size. (105) 
Sensitivity and assessment for publication bias 
Sensitivity analyses were, where possible, undertaken by comparing the summary estimates obtained by 
excluding studies judged to be at high ROB with those judged to be at low or moderate ROB.   
Where possible, publication bias was assessed through the creation of funnel plots, and tested by Begg's 
rank correlation test and Egger's regression test.(13,14) 
Subgroup analyses 
A number of sub-group analyses were undertaken,details of which are in the protocol. 
Registration and reporting 
This review has been registered with the International Prospective Register of Systematic Reviews 
(PROSPERO): CRD42016035372.  The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist was used to guide the reporting of the systematic review (Appendix 2, 
Supplementary file). 
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RESULTS 
Our search strategy yielded 7,490 papers of which 98 studies were eligible; these comprised of 89 double-
blind RCTs (reported in 94 papers), three cost-effectiveness studies and six case series (see Figure 1).  
 
Effectiveness 
Description of studies 
The RCTs enrolled a total of 7,413 patients. The route of administration of AIT was SCIT (n=54), SLIT 
(n=34), and SCIT versus SLIT (n=1). The  majority of trials reported on the short-term effectiveness of 
AIT with only one SLIT trial reporting on long-term effectiveness. The 54 SCIT trials (reported in 57 
papers) included 2,305 patients.(15²70)  and the 34 SLIT trials (71²104)(reported in 36 papers) included 
5,108 patients. SCIT studies included adults (n=24), both children and adults (n=17), and children 
(n=13). SLIT studies included children (n=20), both children and adults (n=10), and adults (n=4). 
Allergen extracts administered included HDM, grass, cat, dog, trees, molds, latex and weeds. Various AIT 
protocols were utilized. The severity of asthma tended to be mild-to-moderate. Further details are 
included in  Tables 1a, 1b, 1c and S1a, S1b, S1c (Supplementary file). 
Quality assessment 
The majority of SCIT trials (n=32) were judged as unclear ROB, seven  low ROB and 15 studies as at 
high ROB (Table S1d, Supplementary file). Twenty SLIT studies were assessed to be at high ROB; 13 
studies were at unclear ROB; and one study at low ROB (Table S1e, Supplementary file).  The one SCIT 
vs SLIT study was judged to be at a low ROB (Table S1f, Supplementary file).  
Primary outcomes 
Symptom scores 
Short-term  
Fifty-eight (36 SCIT and 22 SLIT ) trials reported on the effect of symptoms at the end of the AIT 
treatment period. We were able to pool data from 15 SCIT and SLIT trials with placebo as comparator. 
The metaanalysis  showed that AIT improved symptom scores with a  standardized mean difference 
(SMD) of -1.11 (95%CI -1.66, -0.56) (Figure 2), these suggesting  a large effect of AIT.(105) 
Sensitivity analysis 
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By excluding studies at high ROB sensitivity analysis confirmed the effect of AIT on asthma symptom 
scores: SMD -1.44 (95%CI -2.14, -0.74) (Figure S2a, Supplementary file).  
Publication bias 
The funnel plot showed possible publication bias as evidenced by an excess of small studies with large 
effect sizes (Figures S2b, Supplementary file). Publication bias was also suggested by the Egger test 
(P=0.024).  There were insufficient studies to undertake the Begg test 
       
Subgroup analyses 
x Children (<18 \HDUVYHUVXVDGXOWV\HDUV: SMD -0.58 (95%CI -1.17, -0.01) in children and 
SMD -1.95 (95%CI -3.28, -0.62)) in adults (Figure 3), supporting AIT effectiveness in both 
children and adults. 
x SCIT versus SLIT: the analyses found that SCIT is effective with SMD -1.64 (95%CI -2.51, -
0.78) and suggested (but did not confirm) that SLIT was effective SMD -0.35 (95%CI -0.75, 
0.05)  (Figure 4); this indirect comparison suggested that SCIT was more effective than SLIT.  
x Treatment duration: SMD -1.15 (95%CI -1.77, -0.53) in those treated for <3 years and SMD -
0.79 (95%CI -1.10, -0.49 LQWKRVHWUHDWHGIRU\HDUV (Figure S2c, Supplementary file), these 
analyses finding that both treatment durations were effective. 
x Mild/moderate versus moderate/severe disease: this subgroup analyses found that  AIT is 
effective for mild/moderate asthma SMD -1.00 (95%CI -1.81, -0.19)   and suggested (but did 
not confirm)  a possible benefit in those with moderate/severe disease SMD -0.23 (95%CI -0.89, 
0.43) (Figure S2d, Supplementary file) 
x Individual allergens: this subgroup analyses found evidence of benefit for AIT with HDM SMD 
-1.41 (95%CI -2.27, -0.55), grass pollen SMD -1.18 (95%CI -2.17, -0.20) and cat/dog dander 
(SMD -0.77 (95%CI -1.48, -0.06)), suggested (but did not confirm) benefit for tree pollen SMD -
0.24 (95%CI -0.91, 0.42), and found no benefit for mold SMD 0.36 (95%CI -0.39, 1.11).  (Figure 
S2e, Supplementary file) 
x Monosensitized/mono-allergic versus polysensitized: there is evidence of AIT benefit in 
monosensitized/mono-allergic patients SMD -4.23 (95%CI -5.53, -2.94) and a suggested benefit 
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(but not confirmed) for  polysensitized patients SMD -0.31 (95%CI -0.65, 0.04) (Figure S2f, 
Supplementary file), 
Long-term  
No studies reported on the long-term effectiveness of AIT on symptom score.  
 
Medication scores 
Short-term   
Forty-two (28 SCIT and 14 SLIT ) studies reported on medication scores.. Pooling of data with placebo 
as the comparator was possible for 10 studies.  Meta-analysis found evidence that AIT improved 
medication scores (i.e. reduced medication use) with a SMD of -1.21 (95%CI -1.87, -0.54) (Figure 5), this 
corresponding to a large effect. 
 
Sensitivity analysis 
Sensitivity analysis for this outcome was not possible as no studies were found to be at high ROB. 
Publication bias 
The funnel plot showed possible publication bias as evidenced by an excess of small studies with large 
effect sizes (Figures S2g, Supplementary file), but this was not confirmed by the Egger test (P=0.09).  
There were insufficient studies to undertake the Begg test. 
Subgroup analyses 
x Children (<18 years) versus adults \HDUVthere is evidence for benefit in children SMD -
0.49 (95%CI -0.98, 0.00) and a suggested benefit (but not confirmed) in adults SMD -4.45 
(95%CI -11.23, 2.32) (Figure 6) 
x SCIT versus SLIT: SMD -1.65 (95%CI -2.52, -0.79) for SCIT and SMD -0.29 (95%CI -0.82, 
0.24) for SLIT (Figure 7), these analyses showing benefit of  SCIT and suggesting (but not 
confirming) benefit from SLIT. 
x Mild/moderate versus moderate/severe disease: SMD -1.59 (95%CI -2.48, -0.70) for 
mild/moderate disease and SMD -0.36 (95%CI -1.03, 0.31) (Figure S2h, Supplementary file), 
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these analyses showing a benefit in those with mild/moderate disease and suggesting (but not 
confirming) benefit in those with moderate/severe disease. 
x Treatment duration: SMD -1.21 (95%CI -1.94, -0.49) for those treated for <3 years andSMD -
1.29 (95%CI -2.00, -0.59) for those UHFHLYLQJ3 years of treatment (Figure S2i, Supplementary 
file), these analyses showing evidence of benefit in both groups. 
x Individual allergens: this subgroup analysis demonstrated a benefit of AIT with  HDM (SMD -
2.10 (95%CI -3.29, -0.91) and tree pollen (one study) (SMD -1.08 (95%CI -1.79, -0.37)) and 
suggested (but not confirmed) a benefit for, grass pollen (SMD -0.06 (95%CI -0.41, 0.28)) and 
molds (SMD -0.65 (95%CI -1.92, 0.62) (Figure S2j, Supplementary file).  
x Monosensitized and mono-allergic versus polysensitized: SMD -1.18 (95%CI -1.16, 0.13) in 
mono-sensitized and mono-allergic and the polysensitized group (SMD -0.36 (95%CI -2.11, 
0.25)) in the polysensitized group (Figure S2k) these analyses suggesting (but not confirming) 
benefit in both groups.  
 
Long-term  
 
No studies reported on the long-term effectiveness of AIT on medication score. 
 
Combined symptom and medication scores 
Short-term  
Six studies (two SCIT, three SLIT studies and one SCIT vs. SLIT) reported a combined assessment of the 
effectiveness of AIT on symptoms and medication usage. Pooling of data was possible for two studies, 
this showing a SMD of 0.17 (95%CI -0.23, 0.58) (Figure 8). 
Sensitivity analysis, assessment of publication bias and subgroup analyses 
These analyses were not possible for this outcome. 
Long-term  
One SLIT study at low ROB reported on this outcome. A five-year double blind placebo RCT by 
Durham (2012) had a three year SLIT tablets or placebo treatment period in grass pollen allergic patients 
followed by a two-year blinded observation period when no active treatment was administered. At the 
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end of the five years the group who had received SLIT were found to have a significant improvement in 
combined asthma symptom and medication scores when compared to placebo for the whole five-year 
period (p=0.049). 
Secondary outcomes 
Asthma control 
 
Seven SLIT studies reported on a measure of asthma control  (see Table S1g for details). 
(77,78,85,88,93,98,100). We were unable to pool data due to the differences in reporting of results. The 
one study at low ROB found that AIT did not improve asthma control(98) .  We found no evidence to 
assess whether SCIT is effective in improving asthma control in allergic asthma patients. 
Quality of life 
Eleven AIT trials reported on a measure of  disease-specific QoL (Table S1h).   
Three SCIT studies (19,35,106), all judged to be at low ROB, reported significant improvements in 
disease-specific QoL. Pooled data from two of these trials (19,35), showed a large treatment effect with 
an SMD of -0.83 (95%CI -1.19, -0.47) in favor of SCIT (Figure 9).  
Seven SLIT trials  reported on disease-specific QoL (77,78,83,88,93,98,100).  We were unable to pool data 
from these studies for meta-analysis due to the variable reporting of results (Table 2). The one low ROB 
trial of SLIT(98)  showed no significant improvement in disease-specific QoL.  
Exacerbations 
Six trials (69,78,80,88,91,98) reported on asthma exacerbations, which were defined in a number of ways 
(Table S1i).  The one SCIT trial at low ROB (69) reported on exacerbations defined by the number of 
courses of oral corticosteroids required to restore asthma control  found no significant difference 
between the SCIT and placebo groups (P-value not given).  Five SLIT studies reported on exacerbations, 
which we were unable to pool due to variations in the ways in which trial results were reported.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
In summary, focusing on the trials at low ROB, the Wang (2006) SCIT trial failed to demonstrate 
evidence of a reduction in exacerbations in those treated with AIT compared with those treated with 
placebo.  Two SLIT trials reported a positive effect of AIT on asthma exacerbations, one in the context 
of reducing the dose of ICS.  
Lung function 
Twenty-five studies, of variable quality, reported on measures of lung function: peak expiratory flow rate 
(PEF), forced expiratory volume  in  1 second (FEV1) and forced expiratory flow at 25²75% of forced 
vital capacity (FEF 25-75%). Data on these outcomes were recorded in a number of ways and at varying 
times throughout the study.  
Peak expiratory flow rate (PEF) 
Fourteen studies reported on this outcome.(16,29,38,43,48,50,61,69,72,73,93,96,107,108) (Table S1j).  
Pooled data from six studies suggested no clear benefit of AIT with a SMD of 0.48 (95%CI -0.21, 1.18) 
(Figure S4a) 
Forced expiratory volume (FEV1) 
Nine studies reported on FEV1. Reporting of data was varied (18,28,43,57,73,93,96,108,109) (Table S1k).  
Data pooled from two studies indicated no clear evidence of benefit associated with AIT with a SMD of 
0.41 (95%CI -0.46, 1.27) (Figure S4a)  
Forced expiratory flow at 25²75% of forced vital capacity (FEF25-75) 
We were able to pool data on FEF 25-75 from three trials (72,96,109) and found an SMD of 0.83 (95%CI 
0.31, 1.35), this suggesting a large beneficial effect of AIT (Figure S4a).  
 
In summary, the evidence identified from meta-analysis evaluating the effect of AIT on lung function in 
allergic asthma supports the effectiveness of AIT on small airways (FEF 25-75%), but with no clear 
evidence of benefit on improving PEF or FEV1.  
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Bronchial provocation tests 
Thirty-one trials reported on bronchial provocation tests. Twenty-one trials looked at allergen specific 
provocation tests and 18 studies evaluated non-specific measures of bronchial hyperreactivity. There was 
a wide variation in reporting of outcome data (Tables S1l and S1m). 
Allergen specific airway hyperreactivity 
Twenty-one trials performed allergen specific bronchial provocation tests (15,17²
20,25,30,31,35,44,48,53,60,62,64,67,70,82,107,108,110). They were of variable quality and were mainly 
SCIT  trials (n=20), SLIT being evaluated in only one trial (82). (Table S1l).  
Pooled data from three SCIT studies, demonstrated a large effect of AIT with a  SMD of 0.93 (95%CI 
0.08, 1.79) (Figure S4b). Furthermore, there was evidence from eight high quality RCTs that SCIT was 
effective in reducing allergen specific bronchial reactivity in patients with allergic asthma 
One SLIT study reported on allergen specific bronchial responsiveness to Artemisia pollen (Leng 1990).  
This study, at moderate ROB, found no significant difference between the SLIT and placebo groups.  
Non- specific airway hyperreactivity 
Eighteen studies reported on this outcome (16²18,20,33,36,48,55,62,67,69,72,73,94,96,106,109,110) 
(Table S1m).  
Pooling of data was possible for metacholine PC20 for three studies which showed an SMD of 0.74 
(95%CI -0.17, 1.66) , showing no clear evidence of benefit for AIT; Histamine PC20 for two studies with 
an SMD of 0.33 (95% CI 0.03, 0.64) favouring AIT and for metacholine PD20 for two studies showing 
an SMD of 0.03 (95%CI -0.32, 0.39) showing no clear evidence in favour of AIT (Figure S4c). We were 
able to combine data from seven of these studies which showed an overall SMD of 0.33 (95%CI 0.01, 
0.64) in favour of AIT (Figure S4d) 
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Cost-effectiveness 
One SCIT and two SLIT studies satisfied the eligibility criteria. (111²113) These included children and 
adults with or without allergic rhinitis (Tables S1m and S1n). The quality appraisal is detailed in Tables  
S1o and S1p. 
Of the three studies included only one focused on patients with allergic asthma who did not also have 
allergic rhinitis.(111)  This study was carried out in Germany and compared SCIT with standard care 
based on a small scale RCT (N=65) with three years of follow-up data. The study used a disease specific 
outcome measure (i.e. mean morning peak flow) with no attempt to convert it to a general quality of life 
measure such as quality adjusted life years (QALYs) making it impossible to assess the cost-effectiveness 
of the treatment. The study found that, over the three years, SCIT was more expensive than standard care 
and performed better than standard care on the disease specific outcome measure. 
The remaining two studies looked at patients with both asthma and allergic rhinitis. SLIT was compared 
with  standard care in an RCT (N=151) with one year of follow-up conducted in Austria, Denmark, 
Germany, Holland, Italy, Spain, Sweden and the UK, and with results evaluated from an English National 
Health Service (NHS) perspective.(112)  This study used one year of treatment data and assumed a 
constant treatment effect over the three year treatment period and the six years following the end of the 
treatment. EQ5D was used to evaluate the treatment outcome. The incremental cost-effectiveness ratio 
,&(5 RI 6/,7 DV FRPSDUHG WR VWDQGDUG FDUH DW  SULFHV ZDV FDOFXODWHG DW  ½ SHU
QALY over the nine year period. The study did not attempt to characterize the uncertainty around this 
estimate. Updating this to 2014/15 prices using Personal Social Services Resource Unit (PSSRU) NHS 
LQIODWLRQLQGLFHVJDYHDQ,&(5RI½SHU4$/<$QRWKHU5&71 ZLWKILYH\HDUVRI
follow-up conducted in Italy comparing SLIT with standard care in patients with asthma and rhinitis  and 
found that patients on SLIT cost less and experienced less symptoms than those on standard care.(113)  
Methods for calculationg the costs were not presented in enough detail to understand the analysis that 
had been performed and there was no attempt to convert the symptom score to a general quality of life 
scale making it impossible to assess the cost-effectiveness of SLIT. 
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Safety 
Data from randomized controlled trials (RCTs) and case series were included to assess the safety of AIT.   
 
RCTs 
Fifty-two RCTs (36 SCIT studies and 16 SLIT) reported safety data  (Tables S3a-f). We were able to pool 
data from 38 of these studies (SCIT=29;SLIT=9) including both local and systemic adverse events (AEs) 
Risk of patients experiencing one or more AE 
AIT delivered by any route (SCIT or SLIT) increased the risk of patients experiencing one or more AE 
(i.e. local and systemic) with a  rate ratio (RR) of 1.74 (95%CI 1.38, 2.2) (Figure S3a). Subgroup analysis 
found that the increased risk was higher for  SCIT RR=2.22 (95% CI 1.48, 3.33) than SLIT RR=1.49 
(95%CI 1.13, 1.98), although this is an indirect comparison.(Figures S3b and S3c) 
Total number of  AEs reported 
AIT delivered by any route (SCIT or SLIT) increased the risk of total AEs (i.e. local and/or systemic) 
with a RR=1.50 (95%CI 1.12, 2.02) (Figure S3d). Subgroup analysis found increased risk both for SCIT( 
RR=1.32 (95%CI 1.01, 1.74) and SLIT (RR=1.93 (95%CI 0.95, 3.95) . (Figures S3e and S3f).  
Risk of systemic AEs 
AIT delivered by any route (SCIT or SLIT) increased the risk of systemic AEs with a RR of 1.85 (95%CI 
1.20, 2.84) (Figure S3g). Subgroup analysis found that there was clearly an increased risk of systemic AEs 
with SCIT RR=1.92 (95%CI 1.19, 3.09), but not for SLIT RR=1.39 (95%CI 0.67, 2.92) (Figures S3h and 
S3i) 
Risk of local AEs 
AIT delivered by any route was not found to increase the risk of local AEs: RR=1.18 (95%CI 0.83, 1.67) 
(Figure S3j). The available data suggested that the risk of local AEs was however substantially greater in 
those receiving SLIT when compared to those receiving SCIT (Figure S3j). 
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Case-series 
We identified six eligible case-series studies in our searches; SCIT (n=5)and  SLIT (n=1). The main 
characteristics of these studies and quality appraisal are presented in Tables S3g and S3h. The reported 
incidence of local AEs varied from 0.66 per patient and 0.33 per injection to 1.8% The reported incidence 
of systemic AEs varied from 0.0074% to 0.06%  
No deaths from AIT were reported in any of these studies.  
 
DISCUSSION 
Statement of principal findings 
This review has found a substantial body of evidence showing that administration of AIT in patients with 
allergic asthma can result in reductions in short-term symptom and medication scores.  These findings do 
however need to be interpreted with caution given that the majority of trials were found to be at high or 
unclear ROB and the possibility of publication bias in relation to both these outcomes.  Further sub-
group analysis confirmed the beneficial effect for SCIT but was questionable for SLIT. There was a more 
modest body of evidence for the combined symptom and medication scores, which meta-analysis 
suggested was ineffective but this was not conclusively demonstrated on account of the wide confidence 
intervals.  We found only one trial, judged to be at low ROB, evaluating long-term outcomes, which 
found a significant improvement in combined symptom and medication scores.  
 
There is evidence for SCIT in  improving  asthma specific quality-of-life and reducing allergen specific 
airway hyperreactivity. In terms of lung function we were unable to demonstrate any significant beneficial 
effect on PEFR and FEV1 however SCIT does have a beneficial effect on FEV25-75. No beneficial 
effect of AIT could be demonstrated on asthma control. As for asthma exacerbations, no beneficial effect 
could be demonstrated for SCIT, but there was limited evidence in favour of SLIT. 
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AIT was associated with a moderate increased risk of AEs, both for SCIT and SLIT. Severe systemic AEs 
were observed, but these were uncommon and mainly occurred with SCIT. No fatalities were reported in 
the studies included in this review.  
 
Strengths and limitations 
To our knowledge, this is the most comprehensive assessment of AIT in asthma ever undertaken.  We 
employed internationally accepted techniques to systematically identify, assess and synthesize a substantial 
body of evidence, which included a number of pre-specified sensitivity and subgroup analyses.   
 
The limitations of this review need to be considered.  First, despite our extensive searches we may not 
have uncovered all relevant evidence on this subject.  Second, we were limited by the heterogeneity in 
approaches used to assess outcomes, which meant we were unable to pool data from all trials or 
undertake all the planned subgroup analyses.  The results of this review, particularly for primary 
outcomes, are based on the trials which we were able to meta-analyse which may not be representative of 
all trials. For example, data for combined scores was only available for six studies of which only two 
could be pooled for meta-analysis the results of which had a wide confidence interval allowing no clear 
conclusion to be drawn. For the subgroup analyses that were undertaken, there was in some cases 
imprecision which impacted on our ability to draw clear conclusions. Third, because of the heterogeneity 
in scoring systems used, we undertook meta-analyses using random-effects modeling and pooled data 
using SMDs, which can be difficult to interpret.  The absolute size of the SMD was used to guide 
assessment of the likely effect size demonstrated. Finally, it needs to be borne in mind that there may 
have been important differences between specific AIT products.  Investigating this issue was how ever 
beyond the scope of this review. 
Interpretaion in the light of the previous literature 
The findings from this review are in keeping with earlier evidence syntheses on this subject (see 
companion paper), which found that SCIT inproved short-term symptom amd medication scores and 
measures of bronchial reactivity, but the evidence for SLIT was less consistent. There was no clear 
improvement of lung function for either SCIT or SLIT.  This present study has built on this body of 
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work by adding a broader range of subgroup analyses, including additional studies at low ROB, and 
achieveing greater precision in summary results.   
Implications for policy, practice and research 
Our findings provide evidence that AIT may be effective in improving  two of our three patient-reported 
primary outcomes over the short-term.  Interpretation of these results is however complicated by 
considerations about the quality of the substantial number of studies and possible publication bias. The 
subgroup analyses suggest that SCIT is likely to be more effective than SLIT, and that AIT may be more 
effective in children than in adults 
Greater standardization of trial designs, looking at the compliance of patients to AIT for the differing 
routes of administration, reporting and choice of outcomes and their reporting so as to facilitate evidence 
syntheses and key subgroup analyses would greatly help to advance the body of evidence underpinning 
AIT in allergic asthma. Future well conducted studies looking at the combined symptom and medication 
score are needed  to determine whether AIT is beneficial for this outcome. We hope that future 
researchers will build on the findings from this systematic review and aim to fill key evidence gaps and 
areas of continuing uncertainty. 
7KHILQGLQJVIURPWKLVUHYLHZZLOOEHXVHGWRLQIRUPWKHGHYHORSPHQWRIUHFRPPHQGDWLRQVIRU($$&,·V
Guidelines on AIT.  We anticipate that this review will report mid 2017. 
 
Conclusions 
There is evidence that AIT in allergic asthma can achieve substantial reductions in short-term symptom 
and medication scores, with subgroup analyses confirming a benefit from SCIT and a questionable 
benefit from SLIT.  These findings however need to be interpreted with caution given concerns about 
study quality and potential publication bias. Further there is evidence showing that SCIT decreases 
allergen-specific airway hypereactivity and improves asthma specific quality-of-life. The effect of AIT on 
asthma control and exacerbations is not conclusive, neither its long-term efficacy after stopping AIT, 
which requires further investigation. More research is needed to establish the  cost-effectiveness of AIT 
but evidence suggest that SLIT is cost-effective in a UK NHS environment.  
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AIT is associated with a modest increase in the risk of AEs, both for SCIT and SLIT.  Severe systemic 
AEs can occur, but are uncommon and mainly associated with SCIT. No fatalities were reported in the 
studies included in this review.  
 
Acknowledgments: We would like to thank Debra De Silva, The Evidence centre for their assistance with data extraction and 
quality assessments; Z Sheikh for technical support . This study is part of the EAACI AIT guidelines project, chaired by 
Antonella Muraro and coordinated by Graham Roberts. 
Funding: EAACI and BM4SIT project (grant number 601763) in the European Union's Seventh Framework Programme FP7. 
 
Contributorship: This review was drafted by Sangeeta Dhami. It was revised following critical review initially by Aziz Sheikh, 
Ioana Agache, Marek Jutel, Susanne Lau, and then by all the co-authors. 
Conflicts of interest: Conflicts of interest: S Dhami: reports grants from EAACI to carry out the review, during the conduct 
of the study; A Kakourou: has nothing to disclose; F Asamoah: reports payment from Evidence-Based Health Care Ltd during 
the conduct of the study; I Agache: consulting fee for ALK and Allergopharma; S Lau: grant from Allergopharma; drug 
monitoring committee immunotherapy Merck; grants and research support  from Merck, Allergopharma; M Jutel: consulting fee 
Anergis, Allergopharma; scientific/governmental grant from NCN Poland; fee for review activities Biomag;  A Muraro: 
consulting fee Meda, Nestle, Nutricia, Novartis, ALK; co-investigator for research protocol for Nestlé and Nutricia; G Roberts: 
Materials for research programme (ALK-Abello), research grant (ALK-Abello), advisory board (ALK-Abello), speaker (Allergy 
Therapeutics, ALK-Abelo); C Akdis: consulting fee Novartis, Boehringer-Ingelheim; stocks Davos Diagnostics, Allimentary 
Health Pharma Davos; research grant Novartis, Allergopharma; M Bonini: has nothing to disclose; O Cavkaytar: has nothing to 
disclose; B Flood: has nothing to disclose; P Gajdanowicz: has nothing to disclose; K Izuhara: reports grants and personal fees 
from Chugai Pharmaceutical Co. Ltd, grants from Shino-test Co. Ltd,  outside the submitted work; Ö Kalayci: has nothing to 
disclose; Ralph Mosges:reports personal fees from ALK, grants from ASIT biotech, personal fees from allergopharma, personal 
fees from Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non-financial 
support from Lofarma, non-financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, 
personal fees from Friulchem, personal fees from Hexal, personal fees from Servier, personal fees from Klosterfrau, non-
financial support from Atmos, personal fees from Bayer, non-financial support from Bionorica, personal fees from FAES, 
personal fees from GSK, personal fees from MSD, personal fees from Johnson&Johnson, personal fees from Meda, personal 
fees and non-financial support from Novartis, non-financial support from Otonomy, personal fees from Stada, personal fees 
from UCB, non-financial support from Ferrero, grants from BitopAG, grants from Hulka, personal fees from Nuvo, grants from 
Ursapharm,  outside the submitted work; O Palomares: received research grants from Inmunotek S.L. under public collaborative 
projects from Spanish Ministry (MINECO)/CDTI: IPT-2012-0639-090000, IDI-20110410 and IDI-20141131,has received fees 
for giving scientific lectures from:Allergic Therapeutics, Amgen, Inmunotek S.L, Stallergenes and Novartis, has participated in 
advisory boards from Novartis; O Pfaar:reports grants and personal fees from ALK-Abelló, grants and personal fees from 
Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding 
B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal 
fees from Lofarma, grants from Biomay, grants from Nuvo, grants from Circassia, grants and personal fees from Biotech Tools 
S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from Novartis Pharma, personal fees from 
MEDA Pharma, grants and personal fees from Anergis S.A., personal fees from Sanofi US Services, personal fees from Mobile 
Chamber Experts (a GA2LEN Partner), personal fees from Pohl-Boskamp,  outside the submitted work; S Smolinska: has 
nothing to disclose; M.Sokolowska: research fellowships and grants from European Academy of Allergy and Clinical 
Immunology (EAACI) and European Respiratory Society (ERS); M Asaria: reports payment from Evidence-Based Health Care 
Ltd during the conduct of the study; G Netuveli: has nothing to disclose; H Zaman: reports payment from Evidence-Based 
Health Care Ltd during the conduct of the study;  A Akhlaq: has nothing to disclose; A Sheikh: reports grants from EAACI, 
during the conduct of the study. 
 
 
 
Additional material: 
Figures and tables for main paper 
Appendix 1: Search strategy 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
Appendix 2: PRISMA Checklist 
S1: Supplementary tables  
S2: Supplementary figures for primary outcomes 
S3: Safety tables and figures 
S4: Supplementary figures for secondary outcomes 
 
 
References 
 
1.  The Global Asthma Report 2014 
http://www.globalasthmareport.org/burden/burden.php. 2014;  
2.  World Health Organization. Global surveillance, prevention and control of chronic 
respiratory diseases: a comprehensive approach, 2007.   
3.  Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C. Cluster analysis and 
clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug;178(3):218±24.  
4.  Lötvall J, Akdis C, Bacharier L, Bjermer L, Casale T, Custovic A. Asthma endotypes: a 
new approach to classification of disease entities within the asthma syndrome. J Allergy 
Clin Immunol. 2011 Feb;127(2):355±60.  
5.  Gough H, Grabenhenrich L, Reich A, Eckers N, Nitsche O, Schramm D. Allergic 
multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort 
MAS. Pediatr Allergy Immunol. 2015;26(5):431±437.  
6.     Dhami S, Nurmatov U, Agache I, Lau S, Muraro A, Jutel M, Roberts G, Akdis C, 
Bonini M,     Calderon M, Casale T, Cavkaytar O, Cox L, Demoly P, Flood B, Hamelmann E, 
Izuhara K, Kalayci Ö, Kleine-Tebbe J, Nieto A, Papadopoulos N, Pfaar O, Rosenwasser L, 
Ryan D, Schmidt-Weber C, Szefler S, Wahn U, van Wijk RG, Wilkinson J, Sheikh A. 
Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl 
Allergy. 2016 Feb 9;6:5. doi: 10.1186/s13601-016-0094-y. eCollection 2015.  
 
7.  Passalacqua G, Baena-Cagnani CE,Bousquet J, Canonica GW, Casale TB,  et al. 
Grading local side effects of sublingual immunotherapy for respiratory allergy: 
Speaking the same language http://www.jacionline.org/article/S0091-6749(13)00528-
9/pdf.  
8.  World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading 
System 
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Immunotherapy
%20Forms/7b-World-Allergy-Organization-Systemic-Reaction-Grading-systemx.pdf.  
9.  Cochrane Risk of bias tool  
http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool
_for_assessing.htm.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
10.  CASP checklist for Economic evaluations 
http://media.wix.com/ugd/dded87_3b2bd5743feb4b1aaac6ebdd68771d3f.pdf Last 
accessed on 3rd September 2015.  
11.  NICE Case Series Risk of Bias tool 
https://www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-
form2.  
12.  Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 
Version 5.0.2 (Chapter 11, Section 11).  
13.  Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for 
publication bias. 1994;50(1088):101.  
14.  Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a 
simple, graphical test. 1997;315(629):34.  
15.  Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study 
with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand. 
May 1971;60(3):264±8.  
16.  Adkinson NF, Eggleston PA, Eney D, Goldstein EO,  Schuberth KC, Bacon JR, et al. A 
controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 
1997;336(5):324±31.  
17.  Alvarez-Cuesta E,Cuesta-Herranz J, Puyana-Ruiz J,Cuesta-Herranz C, Blanco-Quiros 
A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects 
from a double-blind placebo study. J Allergy Clin Immunol. Mar 1994;93(3):556±66.  
18.  Alvarez MJ, Echechipia S, Garcia B, Tabar AI, Martin S, Rico P, et al. Liposome-
entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-
blind, placebo-controlled trial on inflammation, bronchial hyperresponsiveness and 
immediate and late bronchial responses to the allergen. Clin Exp Allergy. Nov 
2002;32(11):1574±82.  
19.  Ameal A, Vega-Chicote JM, Fernandez S, Miranda A,Carmona MJ, Rondon MC, et al. 
Double-blind and placebo-controlled study to assess efficacy and safety of a modified 
allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. Sep 
2005;60(9):1178±83.  
20.    Armentia-Medina A, Tapias JA, Martin JF,Ventas P,Fernandez A. Immunotherapy with 
the storage mite Lepidoglyphus destructor. Allergol Immunopathol (Madr). 
1995;23(5):211±23.  
21.  Arvidsson MB,Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early 
and late phase reactions in lower airways of birch pollen asthmatic patients: a double 
blind placebo-controlled study. Allergy. Jan 2004;59(1):74±80.  
22.  Basomba A, Tabar AI,  de Rojas DH, Garcia BE, Alamar R, Olaguibel JM, et al. 
Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides 
pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic 
patients. J Allergy Clin Immunol. Jun 2002;109(6):943±8.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
23.  Blumberga G,Groes L,Haugaard L,Dahl R. Steroid-sparing effect of subcutaneous SQ-
standardised specific immunotherapy in moderate and severe house dust mite allergic 
asthmatics. Allergy. Jul 2006;61(7):843±8.  
24.  Bodtger U, Poulsen LK, Jacobi, HH,Malling J. The safety and efficacy of subcutaneous 
birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled 
study. Allergy. Apr 2002;57(4):297±305.  
25.  Bousquet J, Calvayrac P, Guérin B, Hejjaoui A, Dhivert H, Hewitt B, et al. 
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo 
and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 
1985;76(5):734±44.  
26.  Bousquet J, Hejjaoui A, Soussana M, et al. Double-blind, placebo-controlled 
immunotherapy with mixed grass-pollen allergoids IV. Comparison of the safety and efficacy 
of two dosages of a high-molecular-weight allergoid. J. Allergy Clin. Immunol. February 
1990; volume 85 number 7  
  
 
27.  Cantani A, Ragno V, Monteleone MA, Lucenti P, Businco L. Enzyme potentiated 
desensitisation in children with asthma and mite allergy: a double blind study. Journal of 
Investigational Allergology and Clinical Immunology 1996;6: 270±6.  
28.  Chakraborty P, Roy I, Chatterjee S, Chanda S, Gupta-Bharracharya S. Phoenix 
sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study 
of immunotherapy in patients with seasonal allergy in an agricultural area of West 
Bengal, India. J Investig Allergol Clin Immunol. 2006;16(6):377±84.  
29.  Creticos PS, Reed CS, Norman PS, Khoury J, Adkinson NF, Buncher CR, et al. 
immunotherapy in adult asthma. New England Journal of Medicine 1996;334:501±6.  
30.  Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, 
multicenter immunotherapy trial in children, using a purified and standardized 
Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986;41(2):131±40.  
31.  Dolz I, Martinez-Cocera C, Bartolome JM,Cimarra M. A double-blind, placebo-
controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year 
period with initial rush immunotherapy. Allergy. Jul 1996;51(7):489±500.  
32.  '¶6RX]D0F, Pepys J, Wells ID, Tai E, Palmer F, Overell BG, et al. Hyposensitisation 
with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of 
clinical and immunological effects. Clinical Allergy 1973;3: 177±93.  
33.  Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled 
study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. 
Allergologia et Immunopathologia 1995;23:58±66.  
34.  Gaddie J, Skinner C, Palmer KN. Hyposensitisation with house dust mite vaccine in 
bronchial asthma. Br Med J. Sep 1976; 4;2(6035):561±2.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
35.  Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. 
Successful management of mite-allergic asthma with modified extracts of 
Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, 
placebo-controlled study. J Allergy Clin Immunol. Nov 2006;118(5):1026±32.  
36.    Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. 
Clinical results. Allergy. 1992;47(3):249±54.  
37.  Hedlin G, Willen S, Browaldh H, Hildebrand H, Holmgren D, Lindfors A. 
Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and 
pharmacotherapy. Journal of Allergy and Clinical Immunology 1999;103(4):609±14.  
38.  Hui Y, Li L, Qian J, Guo Y, Zhang X. Efficacy analysis of three-year subcutaneous SQ-
standardized specific immunotherapy in house dust mite-allergic children with asthma. 
Exp Ther Med. Mar 2014;7(3):630±4.  
39.  Kuna P, Alam R,Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy 
on the production of histamine-releasing factor (HRF) by mononuclear cells from 
patients with seasonal asthma: Results of a double-blind, placebo-controlled, 
randomized study. J Allergy Clin Immunol. 1989;83(4):816±24.  
40.  Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies 
to Alternaria alternata in children. J Allergy Clin Immunol. Feb 2011;127(2):502-508-6.  
41.  Lewis H. Hyposensitisation in mite asthma. The Lancet. 1971 May  
42.  Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a 
standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin 
Immunol. 2000 Sep;106(3).::585-90.  
43.  Maestrelli P, Zanolla L, Pozzan M, Fabbri LM, asthma Regione Veneto Study Group on 
the "Effect of immunotherapy in allergic. Effect of specific immunotherapy added to 
pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house 
dust mite. J Allergy Clin Immunol. Apr 2004;113(4):643±9.  
44.  Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. 
Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. 
Allergy. Sep 1987;41(7):507±19.  
45.   Marques AR, Avila R. Results of a clinical trial with a Dermatophagoides pteronyssinus 
tyrosine adsorbed vaccine. Allergol Immunopathol (Madr). May 1978;6(3):231±5.  
46.  Mosbech H, Dreborg S,Frølund L, Ljungstedt-Påhlman I, Svendsen UG, Søborg M, et 
al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust 
mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. 
Allergy. 1989;44(7):487±98.  
47.  Mosbech H, Dirksen A, Dreborg S, Frolund L, Heinig JH, Svendsen UG, et al. 
Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite 
extract. IV. Occurrence and prediction of side effects. Allergy. Feb 1990;45(2):142±50.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
48.  Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. 
Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin 
Immunol. Sep 1984;74(3 Pt 1):230±9.  
49.  Olsen OT, Frølund L, Heinig J, Jacobsen L, Svendsen UG. A double-blind, randomized 
study investigating the efficacy and specificity of immunotherapy with Artemisia 
vulgaris or Phleum pratense/betula verrucosa. Allergol Immunopathol (Madr). 
1995;23(2):73±8.  
50.  Newton DA, Maberley DJ,Wilson R. House dust mite hyposensitization. Br J Dis Chest. 
1978;72(1):21±8.  
51.  Ortolani C,  Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, et al. Grass 
pollen immunotherapy: a single year double-blind, placebo-controlled study in patients 
with grass pollen- induced asthma and rhinitis. J Allergy Clin Immunol. Feb 
1984;73(2):283±90.  
52.  Pauli G, Bessot JC, Bigot H, Delaume G, Hordle DA, Hirth C, et al. Clinical and 
immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: 
a double-blind placebo-controlled trial. J Allergy Clin Immunol. 1984;74(4 Pt 1):524±
35.  
53.  Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus C. Immunotherapy with 
Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to 
cats. J Allergy Clin Immunol. 1998 Oct;102(4).  
54.  Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of 
hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in 
childhood asthma: in vivo aspects. Clin Allergy. May 1984;14(3):209±19.  
55.  Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative 
study of the effects of short preseason specific immunotherapy and topical steroids in 
patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol. Dec 
2001;108(6):921±8.  
56.  Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal 
asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy 
Clin Immunol. Oct 1986;78(4 Pt 1):590±600.  
57.  Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective 
therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. Feb 
2006;117(2):263±8.  
58.  Sabbah A, Bonnaud F, Sonneville A, Bonneau JC, Pinon H. [Specific immunotherapy 
using Alpha-Fraction-Retard-D. pteronyssinus. Double-blind study in asthma]. Allerg 
Immunol (Leipz). Feb 1991;23(2):58±60.  
59.  Smith AP. Hyposensitisation with Dermatophagoides pteronyssinus antigen: trial in 
asthma induced by house dust. British Medical Journal 1971;4:204±6.  
60.  Sundin B, Lilja G, Graff-Lonnevig V, Hedlin G, Heilborn H, Norrlind K, et al. 
Immunotherapy with partially purified and standardized animal dander extracts. I. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
Clinical results from a double-blind study on patients with animal dander asthma. J 
Allergy Clin Immunol. 1986;77(3):478±87.  
61.  Tabar AI, Lizaso MT, Garcia BE, Gomez B, Echechipia S, Aldunate MT, et al. Double-
blind, placebo-controlled study of Alternaria alternata immunotherapy: Clinical efficacy 
and safety. Pediatr Allergy Immunol. Feb 2008;19(1):67±75.  
62.  Taylor WW, Ohman JL, Lowell FC. Immunotherapy in cat- induced asthma. Double-
blind trial with evaluation of bronchial responses to cat allergen and histamine. J 
Allergy Clin Immunol. May 1978;61(5):283±7.  
63.  Taylor B, Sanders SS, Norman AP. A double blind controlled trial of house mite 
fortified house dust vaccine in childhood asthma. Clin Allergy. 1974 Jan;4(1):35.  
64.  Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to 
dog: a double-blind clinical study. Ann Allergy. 1984;53(1):85±8.  
65.  Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to 
dog. Immunologic and clinical findings of a double-blind study. Annals of Allergy 
1986;57(3):173±9.  
66.  Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late 
asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite 
(Dermatophagoides pteronyssinus). Eur Respir J. Mar 1992;5(3):318±22.  
67.  Van Metre TE, Marsh DG, Adkinson NF, Kagey-Sobotka A, Khattignavong A, Norman 
PS, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. Dec 
1988;82(6):1055±68.  
68.  Vidal C, Tabar AI, Figueroa J, Navarro JA, Sanchez C, Orovitg A, et al. Assessment of 
short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic 
patients. Randomised, double-blind, placebo-controlled trial. Curr Drug Deliv. Mar 
2011;8(2):152±8.  
69.  Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, et al. A double-blind, placebo-
controlled study of house dust mite immunotherapy in Chinese asthmatic patients. 
Allergy. 2006;61(2):191±7.  
70.  Warner J, Price J, Soothill J, Hey E. Controlled trial of hyposensitisation to 
Dermatophagoides pteronyssinus in children with asthma. The Lancet. Oct 1978;  
71.  Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, Fernandez-Caldas E, 
Cuesta-Herranz J, Casanovas M. Sublingual immunotherapy with a standardized cat 
dander extract: evaluation of efficacy in a double blind placebo controlled 
study.[Erratum appears in Allergy. Sep 2007;62(9):1100 Note: Mancebo, E G [corrected 
to Gonzalez-Mancebo, E]]. Allergy. Jul;62(7):810±7.  
72.  Bahçeciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy 
in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr 
Pulmonol. 2001;32(1):49±55.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
73.  Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, 
et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-
dust mites: a double-blind, placebo-controlled study. Allergy. Mar 1999;54(3):249±60.  
74.  Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid 
immunotherapy to grass pollen in children: a double-blind, placebo-controlled, 
randomized trial. Allergy. Dec 2000;55(12):1142±7.  
75.  Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M, et al. [Clinical evaluation for 
sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides 
Farinae Drops]. Zhonghua Erke Zazhi. Oct 2007;45(10):736±41.  
76.  Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen 
tablets in asthmatics with rhinoconjunctivitis. Allergy. Feb 2006;61(2):185±90.  
77.  de Blay F, Kuna P, Prieto L, Ginko T, Seitzberg D, Riis B, et al. SQ HDM SLIT-tablet 
(ALK) in treatment of asthma--post hoc results from a randomised trial. Respir Med. 
Oct 2014;108(10):1430±7.  
78.  Devillier P, Fadel R, Beaumont O. House dust mite sublingual immunotherapy is safe in 
patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy [Internet]. 
2015; Available from: 
http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/168/CN-
01096168/frame.html 
79.  Drachenberg KJ, Pfeiffer P, Urban E. Sublingual immunotherapy - Results from a 
multi-centre, randomised, double-blind, placebo-controlled study with a standardised 
birch and grass/rye pollen extract. [German]. Allergologie. 2001;24(11):525±34.  
80.  Gomez Vera J, Flores Sandoval G, Orea Solano M, Lopez Tiro J, Jimenez Saab N. 
Safety and efficacy of specific sublingual immunotherapy in patients with asthma and 
allergy to Dermatophagoides pteronyssinus. Rev Alerg Mex. 2005 Dec;231±6.  
81.  Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al. 
Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy 
Immunol. Jun 2003;14(3):216±21.  
82.  Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for 
Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and 
serum-specific IgE antibody. Annals of Allergy 1990;64(1):27±31.  
83.  Lewith GT, Watkins AD, Hyland ME, Shaw S, Broomfield JA, Dolan G, et al. Use of 
ultramolecular potencies of allergen to treat asthmatic people allergic to house dust 
mite: double blind randomised controlled clinical trial.[Summary for patients in J Fam 
Pract. 2002 Jul;51(7):602; PMID: 12160495]. BMJ. Mar 2002 2;324(7336):520.  
84.  Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic 
effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-
blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17(6):408±
15.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
85.  Ma CX, Lu MF, Ge LP, Qian XM, Zhang MZ. Clinical evaluation of sublingual 
allergen specific immunotherapy in treatment to children with bronchial asthma and 
allergic rhinitis. [Chinese]. J Shanghai Jiaotong Univ Med Sci. Jun 2014;34(6):873±6.  
86.  Ma X, Duolikun. Efficacy of sublingual immunotherapy in children with dust mite 
allergic asthma. [Chinese]. Chin J Contemp Pediatr. May 2010;12(5):344±7.  
87.  Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Barasona MJ, García-Cubillana 
A, et al. Efficacy and quality of life with once-daily sublingual immunotherapy with 
grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol. 
2007;17(6):399±405.  
88.  Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, et al. SQ house 
dust mite sublingually administered immunotherapy tablet (ALK) improves allergic 
rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann 
Allergy Asthma Immunol. Feb 2014;114(2):134±40.  
89.  Mosges R, Graute V, Christ H, Sieber HJ, Wahn U, Niggemann B. Safety of ultra-rush 
titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. 
Pediatr Allergy Immunol. Dec 2010;21(8):1135±8.  
90.  Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual 
immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, 
randomized, and placebo-controlled study in Taiwan. Respir Med. Aug 
2006;100(8):1374±83.  
91.  Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of 
long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-
blind, placebo-controlled study. Allergy. Sep 2000;55(9):842±9.  
92.  Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of 
sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to 
Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. Dec 
2003;33(12):1641±7.  
93.  Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual 
immunotherapy efficacy in children with house dust mite- induced allergic asthma 
optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr 
Allergy Immunol. 2007;18(1):47±57.  
94.  Reilly D, Taylor MA, Beattie NG, Campbell JH, McSharry C, Aitchison TC, et al. Is 
evidence for homoeopathy reproducible? Lancet. Dec 1994 10;344(8937):1601±6.  
95.  Reinert M, Reinert U. Oral hyposensitization with pollen solutions and placebos. 
[German]. Prax Klin Pneumol. 1983;37(6):228±31.  
96.  Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. 
Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in 
children allergic to grass pollen. Clin Exp Allergy. Mar 2008;39(3):401±8.  
97.  Tian M, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for 
Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
peripheral blood of children with allergic asthma. Int Forum Allergy Rhinol. May 
2014;4(5):371±5.  
98.  Virchow J, Backer V, Kuna P, Prieto L, Nolte H, Villesen H. Efficacy of a House Dust 
Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A 
Randomized Clinical Trial. JAMA. Apr 2016 26;315(16).  
99.  Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, et al. Double-blind, 
placebo-controlled evaluation of sublingual immunotherapy with standardized olive 
pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due 
to olive pollen sensitization. Allergy. Jul 1998;53(7):662±72.  
100.  Wang L, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite 
sublingual immunotherapy is safe and appears to be effective in moderate, persistent 
asthma. Allergy. Sep 2013;69(9):1181±8.  
101.  Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, et al. 
Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J 
Allergy Clin Immunol. 2014;133(3):846±852e.6.  
102.  Zhang Q, Yasin A, Qu YM, Yong J, Yalkun Y. Efficacy and safety of dust mite 
sublingual immunotherapy for pediatric allergic rhinitis: A meta-analysis. [Chinese]. 
Chin J Evid-Based Med. 2014;14(11):1373±9.  
103.  Zhang X, Jiang D, Liu R, Fang G, Guo Z. Long-term efficacy of Dermatophagoides 
farina drop specific immunotherapy on children with acarid allergic asthma. Pharm Care 
Res. 2015;4.  
104.  Zheng B, Wang G, Yang S. Efficacy of specific sublingual immunotherapy with 
dermatophagoides farinae drops in the treatment of cough variant asthma in children]. 
Zhongguo Dang Dai Er Ke Za Zhi Chin J Contemp Pediatr. 2012;14(8):585±8.  
105.  Cohen J. Statistical Power Analysis for the Behavioral Sciences. Vol. 2nd ed. Hillsdale, 
NJ: Erlbaum; 1988.  
106.  Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies 
to Alternaria alternata in children. J Allergy Clin Immunol. Feb 2011;127(2):502-508-6.  
107.  Basomba A, Tabar AI, De Rojas DHF, Garcia BE, Alamar R, Olaguibel JM, et al. 
Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides 
pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic 
patients. J Allergy Clin Immunol. 2002;109(6):943±8.  
108.  Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-
blind house-dust-mite immunotherapy study in asthmatic adults. Allergy Eur J Allergy 
Clin Immunol. 1997;52(8):853±9.  
109.  Pajno GB, Passalacqua G, Vita D, Caminiti L, Parmiani S, Barberio G. Sublingual 
immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with 
Parietaria- induced respiratory allergy: a randomized controlled trial. Allergy. Aug 
2004;59(8):883±7.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
110.  Arvidsson MB, Löwhagen O, Rak S. Allergen specific immunotherapy attenuates early 
and late phase reactions in lower airways of birch pollen asthmatic patients: a double 
blind placebo-controlled study. Allergy. 2004;59(1):74±80.  
111.  Reinhold T, Ostermann J, Thum-Oltmer S, Bruggenjurgen B. Influence of subcutaneous 
specific immunotherapy on drug costs in children suffering from allergic asthma 
(Provisional abstract). Clin Transl Allergy. 2013;3(1):30.  
112. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific 
immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. Dec 
2008;63(12):1624±9.  
113.  Ariano R, Berto P, Incorvaia C, Di Cara G, Boccardo R, La Grutta S, et al. Economic 
evaluation of sublinimal immunotherapy vs symptomatic treatment in allergic asthma. 
Ann Allergy Asthma Immunol. Sep 2009;103(3):254±9.  
 
 
 
 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis 
 
Figures and tables for main paper 
 
 
Table 1a: Overview of SCIT trials (n=54 studies in 57 papers) 
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Uppsala, Sweden) was used.   
        
    
Marques, 
1978, Italy 
 
    X    X  X      X     14 m 
Six syringes numbered in 
order of dose, each 
containing 0.5 ml of D 
pteronyssinus extract 
absorbed into tyrosine 
X      X  
    
Mosbech, 
1989, 
Denmark 
 
    X    X    X    X     2 y 
Biologically standardized 
and purified unmodified Dp 
extract (Pharmalgen). The 
mPEG-modified Dp extract 
was produced by coupling 
activated mPEG-succinate 
to the un- modified Dp 
extract. A buffered solution 
of isotonic saline containing 
0.3 mg/ml albumin, 0.4% 
phenol, and phosphate 0.95 
mg/ml was used for 
mPEG-modified extract. 
X X       
    
Mosbech, 
1990, 
Denmark 
 
    X    X    X         2 y 
Single batch of unmodified, 
purified Dp-extract 
(Pharmalgen)  biologically 
standardized was used. By 
RAST-inhibition, 10-11,000 
BU of this extract equated 
100,000 SQ-U of a similar 
mite allergen extract 
(Aquagen, ALK, Horsholm, 
Denmark). Part of this 
      X  
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batch was modified with 
mPEG (3,000 Daltons).  
The unmodified extract was 
reconstituted in a diluent 
containing 
aluminiumhydroxide, 
whereas no such additive 
was present in the buffered 
saline used for the mPEG-
modified extract. 
Newton, 
1979, UK 
 
    X    X  X           15 m 
Alum-precipitated D. 
farinae 
        
 
 
X 
   
Ohman, 
1984, US 
 
     X   X  X      X     3 m 
Active-treatment vials 
reconstituted in 50% 
glycerine to a concentration 
of 13 units of cat allergen 1 
per millilitre 
      X  
 
 
X 
  
 
X 
 
 
X 
Olsen, 
1997, 
Denmark 
 
    X    X  X      X     1 y 
Active treatment with 
extracts of either 
Dermatophagoides 
pterotryssinus (Dpt) or D. 
farinae (Dfa) (Alutard® SQ, 
ALK, Denmark). 
X X     X  
 
 
 
X 
   
 
X 
Ortolani, 
1984, Italy 
 
X        X  X      X     6 m 
Aqueous lyophilized extract 
(Hollister-Stier, Spokane, 
Washington) of  89 velvet, 
1/3 sweet vernal, and  89 
timothy grass pollen 
X        
    
Pauli, 
1984, (not 
stated. 
Authors from 
France & 
UK)  
 
    X    X  X      X     1 y 
Dpt tyrosine- adsorbed 
extract 
X X       
    
Pene, 1998 
France 
     X   X  X           
6 
week
s 
         Fel d 1 peptides          
    
 
X 
Price, 1984,      
UK 
 
    X    X  X      X     2 y 
Tyrosine glutaraldehyde 
modified D. pteronyssinus 
antigen, "Migen', Bencard. 
 X       
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Rak, 2001, 
Sweden 
 
 X       X  X  X    X      
Standardized depot 
preparations of birch pollen 
allergen extract (Alutard 
SQ, ALKAbelló) containing 
water-soluble allergen 
extract and aluminium 
hydroxide 
X X       
   
 
 
X 
 
 
 
X 
Reid, 1986,      
US 
 
X        X    X    X     8 m 
Seven grass mix in serum, 
plus other allergens specific 
to individuals 
X X     X  
    
Roberts, 
2006, UK 
 
X        X  X       X    2 y 
Alutard SQ P pratense 
(ALK-Abello) was used. 
This is an alum-adsorbed 
preparation of pollen from 
P pratense with a 
recommended dose of 
100,000 SQ-U. 
X X     X  
 
 
X 
 
 
X 
  
Sabbah, 
1991, France 
 
    X    X  X      X     180 d 
Alpha-Fraction-Retard-D. 
pteronyssinus 
X X     X  
    
Smith, 
1971,        
UK 
 
    X    X    X    X      HDM extract X X     X  
    
Sundlin, 
1986, Sweden 
 
     X X   X X      X     18 m 
Partially purified, 
standardized allergenic 
extracts of cat  or dog 
dander 
      X  
   
 
X 
 
 
X 
Tabar, 
2008,  Spain 
 
   X     X  X      X     1 y 
Metabolic extract of A. 
alternata that had been 
biologically standardised 
X X     X  
 
 
X 
   
Taylor, 
1978, US 
 
     X   X  X      X     4 m 1.6 mg/ml cat allergen       X  
 
 
X 
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Taylor, 
1978, UK 
    X    X  X      X     10 w 
HDM fortified house dust 
vaccine 
      X  
 
 
X 
   
Valovirta, 
1984,  
Finland 
 
      X  X  X      X     1 y 
Commercial standardised 
aluminium hydroxide 
bound dog dander extract 
(Alutard SQ) 
        
   
 
X 
 
 
X 
Valovirta, 
1986, Finland 
2nd paper 
original study 
1984 
 
      X  X  X      X     1 y 
Commercial standardised 
aluminium hydroxide 
bound dog dander extract 
(Alutard SQ) 
X      X  
    
Van Bever, 
1992, 
Belgium 
 
    X    X  X        X   1 y 
Aqueous extract of 
Dermatophagoides 
pteronyssinus (10 BU·ml 1) 
X        
 
 
X 
   
 
X 
Van Metre, 
1988, US 
 
     X   X  X      X     2 y 
Cat allergenic extract ALK 
1209/229452 was supplied 
by  Allergologisk 
Laboratories, Copenhagen, 
Denmark 
      X  
 
 
X 
  
 
X 
 
 
X 
Vidal, 2011,   
Spain 
 
    X    X  X           4 m 
D. pteronyssinus extract 
with the major allergens 
Der p 1 and 2 
 X     X  
  
 
X 
  
Wang 2006 
China 
    X    X  X           52w 
Dermatophagoides 
pteronyssinus extract 
X X     X  
 
 
X 
 
 
X 
  
 
X 
Warner, 1978 
UK 
    X    X  X           
1 
year 
D. pteronyssinus absorbed 
LQWRW\URVLQH·0LJHQ·
Bencard). 
X X     X  
  
 
X 
  
 
X 
 
AIT, allergen specific  immunotherapy; d, day; HDM , house dust mite; m, month; NR, not reported;  SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; w, week; y, year 
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Table 1b: Overview of SLIT trials (n=34 studies in 36 papers) 
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Author, year, 
country 
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B
ro
n
ch
ia
l  
te
st
st
es
ts
 
Alvarez-Cuesta, 
2007, Spain      
X 
  
X 
 
X 
     
X 
    
1 y 
Aqueous solution of 
standardized semi-
purified cat dander 
extract 
X X X 
     
    
Bachelier, 2001, 
Turkey     
X 
   
X 
 
X 
     
X 
    
26 w 
Dermatophagoide(D.pte
ronyssinus)+Dermatoph
agoidesfarinea 
(D. farinea) 50/50 
extract 
X X 
    
X 
 
 
 
 
 
X 
 
 
 
 
X 
  
 
 
X 
Bousquet, 
1999, France     
X 
   
X 
 
X 
     
X 
    
108 w. HDM SLIT X X X 
   
X X 
 
X 
 
X 
  
X 
 
Caffarelli, 2000, 
Italy 
X 
       
X 
 
X 
     
X 
    
13 w 
and 9 
week 
follow 
up 
post 
treatm
ent 
Grass pollen tablet (33% 
Holcus lanatus, 33% 
Phleum pratense and 
33% Poa pratensis) 
X X X 
   
X 
 
    
Cao, 2007, 
China     
X 
   
X 
 
X 
     
X 
    
3 m 
Dermatophagoides 
Farinae Drops  
X 
    
X 
 
 
 
X 
 
X 
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Dahl, 2006, 
Denmark & 
Sweden 
X 
       
X 
 
X 
  
X X 
 
X 
    
19.5 w 
Timothy grass 
(Phleumpratense) 
GRAZAX tablet 75,000 
SQ-T once daily 
X X 
      
    
de Blay, 2014, 
Denmark, 
Germany, Italy, 
Spain, UK, 
Sweden, France 
& Poland 
    
X 
   
X 
 
X 
 
X 
   
X 
    
1 y 
Oral lyophilisates 
containing standardized 
extracts of D 
pteronyssinus and D 
farinae in a 1:1 ratio. 
One development unit 
corresponds to 1 SQ-
HDM 
  
X 
   
X X 
 
 
 
 
X 
 
 
 
 
X 
  
Devillier, 2015, 
China     
X 
   
X 
 
X 
     
X 
    
"52 w 
(+ 12 
week 
baselin
e 
period  
before 
rando
misati
on)" 
HDM SLIT (D. 
pteronyssinus and D. 
farinae), approximately 
28 mcg Der P 1 and 
50mcg Der f 1 daily  
(300 IR) 
      
X X 
 
 
 
 
 
X 
  
 
 
 
 
X 
 
Drachenberg, 
2001, Germany 
X 
       
X 
 
X 
     
X 
    
6 m 
Standardized allergen 
extract (ORALVAC 
birch n = 21 resp. 
grass/rye = 28) 
  
X 
    
X 
    
Durham, 2012 X        X  X   X X  X     
5y(3 
Rx, 2 
follow
up) 
Timothy grass 
(Phleumpratense) 
GRAZAX tablet 75,000 
SQ-T once daily 
     x   
    
Gomez Vera et 
al, 2005, 
Mexico 
    
X 
   
X 
 
X 
     
X 
    
6 m 
Dermatophagoides  
pteronyssinus 1 
standardized  
allergens (IPI-ASAC, 
Mexico) at  
a total dose of 10,469 
UBE 
 
 
X 
    
X 
 
 
 
 
 
X 
  
 
 
 
X 
 
Ippoliti, 2003, 
Italy      
X 
  
X 
 
X 
     
X 
    
26 w 
(with 
3-
month 
run-in) 
HDM SLIT (D. 
pteronyssinus), 
maintenance dose 5 
drops of 10 BU/mL 3 
times a week 
X 
       
 
 
 
X 
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Leng, 1990, 
unclear country   
X 
    
X X 
 
X 
     
x 
    
7.14 w 
(13 w 
post-
treatm
ent 
follow
-up) 
Artemisia pollen SLIT 
daily up-dosing to a 
maximum of 16416 
PNU. Cumulative dose 
396,652.06 PNU 
      
X 
 
    
 
 
 
X 
Lewith, 2002, 
UK     
X 
   
X 
 
X 
         
X 16 w. 
Homeopathic HDM 
SLIT administered on 3 
occasions over 24 hours. 
Dose 30 dilutions of 
1:100 
       
X 
 
 
X 
   
Lue, 2006, 
Taiwan     
X 
   
X 
 
X 
     
X 
    
24 w 
(2 eeks 
post-
treatm
ent 
follow
-up) 
HDM SLIT daily with 3 
week initiation phase. 
Maximum  20 drop dose 
of 300 IR/mL. 
Cumulative dose of 
41,824 IR 
X X 
      
 
 
X 
   
Ma, 2010, 
China     
X 
   
X 
  
X X 
   
X 
    
1 y 
SLIT immunotherapy 
with Der F drops 
X 
     
X 
 
X X   
Ma, 2014, 
China     
X 
   
X 
 
X 
     
X 
    
1 y 
SLIT immunotherapy 
with Der F drops  
X 
    
X 
 
    
Moreno-
Ancillo, 2007, 
Spain 
X 
      
X 
 
X X 
     
X 
    
248 d 
biologically standardized 
by major allergens and 
quantified in 
micrograms, without up-
dosing 
X X X 
     
    
Mosbech, 2014, 
Denmark, 
Germany, Italy, 
Spain, UK, 
Sweden, France 
& Poland 
    
X 
   
X 
 
X 
 
X 
   
X 
    
52 w 
(1 y 
treatm
ent 
durati
on) 
Orallyophilisates 
containing standardized 
extracts of 
Dpteronyssinus and D 
farinae in a 1:1 ratio. 
Three active strengths 
were investigated: 1, 3, 
and 6 SQ-HDM. The 
units were designated in 
development units. One 
development unit 
corresponds to 1 SQ-
HDM. 
X 
     
X X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Mosges et al, 
2010, 
Germany 
X 
       
X 
 
X 
         
X 9 m 
Standardized birch 
pollen (Betula alba) 
allergen extract.  Ultra-
rush high-dose SLIT 
titration regimen 
      
X 
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reaching the 
maintenance dose of 300 
IR 
within 90 min (30²90²
150²300 IR) 
X 
Niu, 2006, 
Taiwan     
X 
   
X 
 
X 
 
X 
        
24 w 
(+2 
week 
off-
treatm
ent 
follow 
up) 
HDM SLIT (D. 
Pteronyssinus  and D. 
farinae), incremental 
dosing up to 
maintenance dose 
(cumulative dose ~ 
41824 IR, which was 
equivalent to 1.7 mg 
D.p. and 3.0 mg D.f.) 
X X 
    
X 
 
 
 
 
 
X 
   
Pajno, 2000, 
Italy     
X 
   
X 
 
X 
 
X 
        
104 w  
HDM SLIT (D. 
pteronyssinus), 
incremental dosing 
schedule followed by 
maintenance 2.4 mg Der 
P 1 and 1.2 mg Der P 2 
per week (in 3 
doses/wk) 
 
X X 
   
X 
 
   
 
 
 
 
X 
 
Pajno, 2002, 
Italy         
X 
 
X 
 
X 
        
56 w 
(with 
52 
week 
off-
treatm
ent 
follow
-up) 
Parietaria pollen SLIT 
(Parietariajudaica), 
incremental dosing 
schedule followed by 
maintenance twice/wk 
(cumulative Par j ~ 20.3 
mcg) 
X X 
      
    
Pajno, 2004, 
Italy 
 
  
X 
    
X X 
 
X 
     
X 
    
56 w  
(with 
52 
week  
off-
treatm
ent  
follow
-up) 
 
Parietaria pollen SLIT 
(Parietaria judaica), 
incremental dosing 
schedule followed by 
maintenance twice/wk 
(cumulative Par j ~ 20.3 
mcg) 
 
        
 
 
 
 
X 
 
 
  
 
 
 
X 
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Pham-Thi, 
2007, France     
X 
   
X 
 
X 
     
X 
    
78 w. 
HDM SLIT (D. 
Pteronyssinus and 
D.farinae), up-dosing for 
2 w up to 300 IR 
concentration once daily 
(average cumulative dose 
was 155,000 IR, 
corresponding to 6.9 mg 
Der P 1 and 14.7 mg 
Der f 1) 
X X 
    
X X 
 
 
 
 
 
X 
 
 
 
 
 
X 
  
Reilly, 1994, 
UK    
X X 
  
X X 
 
X 
     
X 
    
4 w 
(with 4 
w 
'option
al' 
post-
treatm
ent 
follow
-up) 
Homeopathic SLIT 
(allergen varied, decided 
on case-by-case basis; 
HDM (84.6% of 
participants); feathers 
(7.7%); mixed moulds 
(7.7%)). 3 doses in 24 
hours then optionally 
repeated at 4 w 
(according to patient 
choice) 
  
X 
   
  
 
 
 
 
 
X 
   
X 
Reinert, 1983, 
Germany 
X 
       
X 
 
X 
     
X 
    
2 y Troponholistersteir 
  
X 
     
    
Stelmach, 2009, 
Poland 
X 
       
X 
 
X 
         
X 104 w. 
Grass pollen SLIT 
(Dactylisglomerata, 
Anthoxanthumodoratu
m, Loliumperenne, 
Poapratensis, Phleum 
pretense). Ultra-rush 
period(total of 24 0IR). 
At the beginning of the 
next day, every morning 
before breakfast, 
received 4 puffs (120 IR) 
for 6 m. Cumulative 
dose 43,800 IR 
X X 
    
X 
 
 
 
 
 
 
 
X 
   
 
 
 
 
 
X 
Tian, 2014, 
China     
X 
   
X 
 
X 
     
X 
    
48 w. 
HDM SLIT (D. farinae), 
titrated up over the first 
4 w to 333 mcg/mL 
once daily 
X 
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Virchow, 2016, 
Germany     
X 
   
X 
 
X 
          
20 m 
(11 
Augus
t 2011 
to 24 
April 
2013) 
HDM SLIT tablet 
contains extract from 2 
species of cultivated 
HDM (D pteronyssinus 
and D farinae), 
produced in a 
standardized process 
with a 1:1:1:1 ratio of 
the major allergens 
(Group1 allergens of D 
farinae and D 
pteronyssinus and 
Group2 allergens of D 
farinae and D 
pteronyssinus), and 
formulated as rapidly 
dissolving oral 
lyophilisate for 
sublingual 
administration (ALK). 
X 
     
X 
 
   
 
 
 
 
 
 
 
 
 
 
X 
 
Vourdas, 1998, 
Greece  
X 
      
X 
 
X 
          
104 w 
(2 y) 
Olive pollen SLIT, daily 
up-dosing then each 
morning pre- and co-
seasonally from January 
to July for 2 y up to a 
maximum of 20 drops 
of 300 IR (total 30,000 
IR/y) 
X X 
    
X 
 
 
 
 
X 
   
Wang, 2014, 
China  
X 
      
X 
 
X 
          
52 w 
(+12 
w 
baselin
e 
period 
before 
rando
misati
on) 
HDM SLIT 
(D.pteronyssinus and D. 
farinae), approximately 
28 mcg Der P 1 and 50 
mcg Der f 1 daily (300 
IR) 
X X 
    
X X 
 
 
 
 
 
X 
 
 
 
 
 
X 
  
Wood, 201, US 
& UK        
X X 
 
X 
  
X 
 
X 
     
13  w. 
Greer German 
cockroach extract 
 
     
X 
 
    
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
Zhang, 2013, 
China     
X 
   
X 
  
X 
         
36 m 
Standard 
dermatophagoides  
farinae drops (1~4) 
usage:1~3  
were for increasing 
period of  
treatment for 3 w, 1 
times  
a day.  
 
        
    
Zhang, 2015, 
China     
X 
   
X 
  
X 
         
36 m 
Dermatophagoides 
farina drop  
(1drop/time and 1 
time/day) 
 
        
    
Zheng et al, 
2012, China 
    X    X   X          
36 
month
s 
Standard 
dermatophagoides 
farinae drops 
        
    
 
AIT, allergen specific  immunotherapy; d, day; HDM , house dust mite; m, month; NR, not reported;  SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; w, week; y, year 
 
 
 
Table 1c: Overview of SCIT vs SLIT trials (n=1) 
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Yukselen,20
12, Turkey 
 
    X    X  X  X    X      
HDM (D. pteronyssinus 
and  D. farinae)  (50/50) for 
sublingual and 
subcutaneous 
administration.  
 
X X     X  
 
 
X 
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Figure 1: PRISMA diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
N = 7430 
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Additional records identified 
through other sources 
N = 60 
Records after duplicates removed 
N = 5997 
Records screened 
N = 5997 
Records excluded 
N = 5683 
Full-text articles 
assessed for eligibility 
N = 314 
Full-text articles 
excluded, with reasons 
N = 216 
Studies included in 
qualitative synthesis 
N = 98  
(54 SCIT, 34 SLIT, 1 SCIT 
vs SLIT, 6 case series, 3 
HE) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
N = 15 
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Figure 2: Meta-analysis of double-blind RCTs for symptom scores comparing AIT (SLIT and 
SCIT) and placebo groups (random effects model) 
 
 
 
 
 
Test of ES=0: z=   3.96 p = 0.000 
Heterogeneity chi-squared = 234.28 (d.f. = 14) p = 0.000 
I-squared (variation in ES attributable to heterogeneity) = 94.0% 
Estimate of between-study variance Tau-squared = 1.0488 
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Figure 3: Meta-analysis of double-blind RCTs, comparing symptom scores between AIT (SLIT 
and SCIT) and placebo groups in FKLOGUHQYHUVXVDGXOWV years(random effects model) 
 
 
 
 
Test(s) of heterogeneity: 
  Heterogeneity degrees of 
  Statistic  freedom P Isquared** Tau-squared 
 
Adult  61.83  4  0.000 93.5%  2.0670 
Children                   34.02  4  0.000 88.2%  0.3750 
Overall  104.04  9  0.000 91.3%  0.7215 
 
 
Significance test(s) of ES=0 
 
Adult                 z=  2.87     p = 0.004 
Children              z=  1.93     p = 0.054 
Overall               z=  3.87     p = 0.000 
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Figure 4: Meta-analysis of double-blind RCTs, comparing symptom scores between SCIT versus 
SLIT (random effects model) 
 
  
 
 
 
              Heterogeneity   degrees of 
 Statistic  freedom                     P  Isquared**            Tau-squared 
 
SCIT 137.11  8  0.000  94.2%  1.5937 
SLIT 23.26  5  0.000  78.5%  0.1810 
Overall 234.28  14  0.000  94.0%  1.0488 
 
 
SCIT                  z=  3.71     p = 0.000 
SLIT                  z=  1.71     p = 0.087 
Overall               z=  3.96     p = 0.000 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
 
 
 
Figure 5: Meta-analysis of double-blind RCTs, comparing medication scores between AIT (SLIT 
and SCIT) and placebo groups (random effects model) 
 
 
 
 
 
 
Test of ES=0 : z=   3.56 p = 0.000 
 Heterogeneity chi-squared = 112.48 (d.f. = 9) p = 0.000 
 I-squared (variation in ES attributable to heterogeneity) =  92.0% 
 Estimate of between-study variance Tau-squared =  0.9967 
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Figure 6: Meta-analysis of double-blind RCTs, comparing medication scores between AIT (SLIT 
and SCIT) and placebo groupVLQFKLOGUHQYHUVXVDGXOWV\HDUV(random effects model) 
 
 
 
 
                 Het.stat.      df P I-squared** Tau-squared 
 
Adult 35.08 1 0.000 97.1%  23.2029 
Children 15.79 4 0.003 74.7%  0.2244 
Overall 66.41 6 0.000 91.0%  0.9722 
 
 
Adult                 z=  1.29     p = 0.197 
Children              z=  1.96     p = 0.050 
Overall               z=  2.89     p = 0.004 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
 
Figure 7: Meta-analysis of double-blind RCTs, comparing medication scores between SLIT and 
SCIT  (random effects model) 
 
 
 
 
 
                    Het.  statistic   df     P         I-squared**   Tau-squared 
 
SCIT                66.59          6      0.000      91.0%        1.1642 
SLIT                 7.14           2      0.028      72.0%        0.1553 
Overall            112.48         9      0.000      92.0%        0.9967 
Significance test(s) of ES=0 
 
SCIT                  z=  3.74     p = 0.000 
SLIT                  z=  1.06     p = 0.287 
Overall               z=  3.56     p = 0.000 
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Figure 8: Meta-analysis of double-blind RCTs, comparing combined symptom medication 
scores between AIT (SLIT and SCIT) and placebo groups (random effects model) 
 
 
 
 
 
Test of SMD=0 : z=   0.84 p = 0.400 
 Heterogeneity chi-squared =   0.12 (d.f. = 1) p = 0.728 
 I-squared (variation in SMD attributable to heterogeneity) =   0.0% 
 Estimate of between-study variance Tau-squared =  0.0000 
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Figure 9: Meta-analysis of double blind RCTs of AIT (SCIT and SLIT) versus placebo 
for asthma specific quality of life (random effects model) 
 
 
 
 Test of SMD=0 : z=   4.48 p = 0.000      
  Heterogeneity chi-squared =   0.02 (d.f. = 1) p = 0.893 
  I-squared (variation in SMD attributable to heterogeneity) =   0.0% 
  Estimate of between-study variance Tau-squared =  0.0000 
 
 
 
 
 
